Guangdong HEC Pharma swings to H1 FY26 net loss of RMB 603.72 million; revenue drops 44.5% to RMB 1.08 billion

• Guangdong HEC Pharmaceutical posted revenue of RMB 1.08 billion, down 44.5% for the six months ended June 30, 2026.
• Net loss attributable to equity shareholders widened to RMB 596.42 million, swinging from a loss of RMB 54.27 million a year earlier.
• Basic and diluted loss per share was RMB 1.09, while the board again declared no interim dividend.
• FDA marketing approval for Insulin Glargine Injection came in April, with the first commercial shipment to the U.S. completed in July.
• China approvals included Olorigliflozin Capsules in January, while Vonoprazan Fumarate and Sodium Chloride Injection entered NDA review in April.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangdong HEC Pharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12308197), on August 31, 2026, and is solely responsible for the information contained therein.